close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gilead Sciences, Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
U.S. FDA Approves Expanded Indication for Gilead’s Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
From Gilead Sciences, Inc.
Via Business Wire
Tickers CBAY GILD
News headline image
Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Ted Love, MD, Joins Gilead Sciences’ Board of Directors
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Provides Update on Phase 3 EVOKE-01 Study
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers CGEN GILD
News headline image
Analyses of Kite’s Yescarta® CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023 Demonstrate High Rate of Durable Response in Patients With High-Risk Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Tickers ACLX GILD
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces Third Quarter 2023 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD RCUS
News headline image
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
News headline image
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
From Gilead Sciences, Inc.
Via Business Wire
Tickers GILD
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.